- Home
- AMSF vs DBVT Comparison
AMSF vs DBVT Comparison
Compare AMSF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | DBVT |
|---|---|---|
| Founded | 1985 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.9M | 769.4M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMSF | DBVT |
|---|---|---|
| Price | $38.07 | $17.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $58.33 | $31.75 |
| AVG Volume (30 Days) | 150.3K | ★ 575.0K |
| Earning Date | 02-25-2026 | 10-28-2025 |
| Dividend Yield | ★ 6.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.60 | N/A |
| Revenue | ★ $309,746,000.00 | $5,502,000.00 |
| Revenue This Year | $4.26 | $1,768.71 |
| Revenue Next Year | $4.48 | $1,028.88 |
| P/E Ratio | $14.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.34 | $3.80 |
| 52 Week High | $53.27 | $26.19 |
Technical Indicators
Market Signals| Indicator | AMSF | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 49.16 |
| Support Level | $37.17 | $16.69 |
| Resistance Level | $38.11 | $18.40 |
| Average True Range (ATR) | 0.85 | 1.04 |
| MACD | 0.03 | -0.37 |
| Stochastic Oscillator | 42.46 | 28.45 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.